ID,Name,NCI Codelist Code,Data_Type,Term,NCI Term Code,Decoded_Value,Numeric_Value,Order,Notes,XL Comments
AREL,Analysis Causality,,text,RELATED,,,,,,
AREL,Analysis Causality,,text,NOT RELATED,,,,,,
AEREL,AE Causality,,text,Multiple,,,,1,,
AEOUT,Outcome of Adverse Event,C66768,text,FATAL,C48275,,,1,,
AEOUT,Outcome of Adverse Event,C66768,text,NOT RECOVERED/NOT RESOLVED,C49494,,,2,,
AEOUT,Outcome of Adverse Event,C66768,text,RECOVERED/RESOLVED,C49498,,,3,,
AEOUT,Outcome of Adverse Event,C66768,text,RECOVERED/RESOLVED WITH SEQUELAE,C49495,,,4,,
AEOUT,Outcome of Adverse Event,C66768,text,RECOVERING/RESOLVING,C49496,,,5,,
AEOUT,Outcome of Adverse Event,C66768,text,UNKNOWN,C17998,,,6,,
AETOXGR,AETOXGR,,text,1,,Grade 1,1,1,,
AETOXGR,AETOXGR,,text,2,,Grade 2,2,2,,
AETOXGR,AETOXGR,,text,3,,Grade 3,3,3,,
AETOXGR,AETOXGR,,text,4,,Grade 4,4,4,,
AETOXGR,AETOXGR,,text,5,,Grade 5,5,5,,
AETRTGV1,Treatment Given 1,,text,NO TREATMENT GIVEN,,,,1,,
AETRTGV2,Treatment Given 2,,text,MEDICATION,,,,1,,
AETRTGV3,Treatment Given 3,,text,SURGERY/PROCEDURE,,,,1,,
AETRTGV4,Treatment Given 4,,text,RADIATION,,,,1,,
AETRTGV5,Treatment Given 5,,text,TRANSFUSION,,,,1,,
AETRTGV6,Treatment Given 6,,text,OTHER TREATMENT,,,,1,,
ADURU,Analysis Duration Unit,C71620,text,DAYS,C25301,,,1,,
AGEGR1,Age Grouping 1,,text,< 65,,,1,1,,
AGEGR1,Age Grouping 1,,text,>= 65,,,2,2,,
AGEGR2,Age Grouping 2,,text,< 75,,,1,1,,
AGEGR2,Age Grouping 2,,text,>= 75,,,2,2,,
AGEGR3,Age Grouping 3,,text,< 65,,,1,1,,
AGEGR3,Age Grouping 3,,text,65 to < 75,,,2,2,,
AGEGR3,Age Grouping 3,,text,75 to < 85,,,3,3,,
AGEGR3,Age Grouping 3,,text,>= 85,,,4,4,,
AGEU,Age Unit,C66781,text,YEARS,C29848,,,,,
COHORT,Cohort,,text,ESC A: SOLID TUMOR XL092 100+NIVO360,,ESC A: SOLID TUMOR XL092 100+NIVO360,1,1,,
COHORT,Cohort,,text,ESC B: SOLID TUMOR XL092 40+NIVO3+IPI1,,ESC B: SOLID TUMOR XL092 40+NIVO3+IPI1,2,2,,
COHORT,Cohort,,text,ESC B: SOLID TUMOR XL092 60+NIVO3+IPI1,,ESC B: SOLID TUMOR XL092 60+NIVO3+IPI1,3,3,,
COHORT,Cohort,,text,ESC B: SOLID TUMOR XL092 80+NIVO3+IPI1,,ESC B: SOLID TUMOR XL092 80+NIVO3+IPI1,4,4,,
COHORT,Cohort,,text,ESC D: SOLID TUMOR XL092 60+NIVO480+RELAT480,,ESC D: SOLID TUMOR XL092 60+NIVO480+RELAT480,5,5,,
COHORT,Cohort,,text,ESC D: SOLID TUMOR XL092 100+NIVO480+RELAT480,,ESC D: SOLID TUMOR XL092 100+NIVO480+RELAT480,6,6,,
COHORT,Cohort,,text,EXP 1: CCRCC 1L XL092 100+NIVO480,,EXP 1: ccRCC1L XL092 100 mg + Nivo 480 mg,11,7,,
COHORT,Cohort,,text,EXP 1: CCRCC 1L XL092 100+NIVO480+RELAT480,,EXP 1: ccRCC1L XL092 100 mg + Nivo/Rela FDC,12,8,,
COHORT,Cohort,,text,EXP 2: CCRCC 2L XL092 100,,EXP 2: ccRCC2L XL092 100 mg,21,9,,
COHORT,Cohort,,text,EXP 2: CCRCC 2L XL092 100+NIVO480,,EXP 2: ccRCC2L XL092 100 mg + Nivo 480 mg,22,10,,
COHORT,Cohort,,text,EXP 3: MCRPC XL092 100,,EXP 3: mCRPC XL092 100 mg,31,11,,
COHORT,Cohort,,text,EXP 3: MCRPC XL092 100+NIVO480,,EXP 3: mCRPC XL092 100 mg + Nivo 480 mg,32,12,,
COHORT,Cohort,,text,EXP 6: NCCRCC 1L XL092 100,,EXP 6: nccRCC (1L) XL092 100 mg,61,13,,
COHORT,Cohort,,text,EXP 6: NCCRCC 1L XL092 100+NIVO480,,EXP 6: nccRCC (1L) XL092 100 mg + Nivo 480 mg,62,14,,
COHORT,Cohort,,text,EXP 7: HCC 1L XL092 100+NIVO480,,EXP 7: HCC (1L) XL092 100 mg + Nivo 480 mg,71,15,,
COHORT,Cohort,,text,EXP 7: HCC 1L XL092 100+NIVO480+RELAT480,,EXP 7: HCC (1L) XL092 100 mg + Nivo/Rela FDC,72,16,,
COHORT,Cohort,,text,EXP 10: MSS CRC 2L XL092 100+NIVO480,,"EXP 10: CRC (MSS, 2L+) XL092 100 mg + Nivo 480 mg",101,17,,
COHORT,Cohort,,text,EXP 10: MSS CRC 2L XL092 100+NIVO480+RELAT480,,"EXP 10: CRC (MSS, 2L+) XL092 100 mg + Nivo/Rela FDC",102,18,,
COHORT,Cohort,,text,EXP 11: HNSCC ICI NAIVE XL092 100+NIVO480,,EXP 11: HNSCC (ICI naive) XL092 100 mg + Nivo 480 mg,110,19,,
COHORT,Cohort,,text,EXP 12: CCRCC 2L/3L XL092 60,,EXP 12: ccRCC (2-3L) XL092 60 mg,120,20,,
COHORT,Cohort,,text,EXP 12: CCRCC 2L/3L XL092 100,,EXP 12: ccRCC (2-3L) XL092 100 mg,121,21,,
COHORT,Cohort,,text,EXP 13: CCRCC 1L XL092 60+NIVO480,,EXP 13: ccRCC (1L) XL092 60 mg + Nivo 480 mg,130,22,,
COHORT,Cohort,,text,EXP 13: CCRCC 1L XL092 100+NIVO480,,EXP 13: ccRCC (1L) XL092 100 mg + Nivo 480 mg,131,23,,
CSTAGE,Current Disease Stage,,text,STAGE I,,,,1,,
CSTAGE,Current Disease Stage,,text,STAGE II,,,,2,,
CSTAGE,Current Disease Stage,,text,STAGE III,,,,3,,
CSTAGE,Current Disease Stage,,text,STAGE IV,,,,4,,
CSTAGE,Current Disease Stage,,text,STAGE IVA,,,,5,,
CSTAGE,Current Disease Stage,,text,STAGE IVB,,,,6,,
CSTAGE,Current Disease Stage,,text,STAGE IVC,,,,7,,
CSTGCAT,Disease Stage Categories,,text,Stage I,,,1,2,,
CSTGCAT,Disease Stage Categories,,text,Stage II,,,2,3,,
CSTGCAT,Disease Stage Categories,,text,Stage III,,,3,4,,
CSTGCAT,Disease Stage Categories,,text,Stage IV,,,4,5,,
CSTGCAT,Disease Stage Categories,,text,Missing,,,5,6,,
AREL,AREL,,text,NOT RELATED,,,,1,,
AREL,AREL,,text,RELATED,,,,2,,
ARMCD,ARMCD,,text,XL092_100+NIVO360,,XL092 100 MG + NIVOLUMAB 360 MG,1,1,,
ARMCD,ARMCD,,text,XL092_40+NIVO3+IPI1,,XL092 40 MG + NIVOLUMAB 3 MG/KG + IPILIMUMAB 1 MG/KG,2,2,,
ARMCD,ARMCD,,text,XL092_60+NIVO3+IPI1,,XL092 60 MG + NIVOLUMAB 3 MG/KG + IPILIMUMAB 1 MG/KG,3,3,,
ARMCD,ARMCD,,text,XL092_80+NIVO3+IPI1,,XL092 80 MG + NIVOLUMAB 3 MG/KG + IPILIMUMAB 1 MG/KG,4,4,,
ARMCD,ARMCD,,text,XL092_100,,XL092 100 MG,5,5,,
ARMCD,ARMCD,,text,XL092_100+NIVO480,,XL092 100 MG + NIVOLUMAB 480 MG,6,6,,
ARMCD,ARMCD,,text,XL092_60+NIVO480+RELATLIMAB,,XL092 60 MG + NIVOLUMAB 480 MG + RELATLIMAB 480 MG,7,7,,
ARMCD,ARMCD,,text,XL092_100+NIVO480+RELATLIMAB,,XL092 100 MG + NIVOLUMAB 480 MG + RELATLIMAB 480 MG,8,8,,
ATOXDSH,Analysis Toxicity Description High,,text,Alkaline phosphatase increased,,,,1,,
ATOXDSH,Analysis Toxicity Description High,,text,Alanine aminotransferase increased,,,,2,,
ATOXDSH,Analysis Toxicity Description High,,text,Serum amylase increased,,,,3,,
ATOXDSH,Analysis Toxicity Description High,,text,Aspartate aminotransferase increased,,,,4,,
ATOXDSH,Analysis Toxicity Description High,,text,Blood bilirubin increased,,,,5,,
ATOXDSH,Analysis Toxicity Description High,,text,Hypercalcemia,,,,6,,
ATOXDSH,Analysis Toxicity Description High,,text,Serum creatinine increased,,,,7,,
ATOXDSH,Analysis Toxicity Description High,,text,GGT increased,,,,8,,
ATOXDSH,Analysis Toxicity Description High,,text,Hyperglycemia,,,,9,,
ATOXDSH,Analysis Toxicity Description High,,text,Hyperkalemia,,,,10,,
ATOXDSH,Analysis Toxicity Description High,,text,Blood lactate dehydrogenase increased,,,,11,,
ATOXDSH,Analysis Toxicity Description High,,text,Lipase increased,,,,12,,
ATOXDSH,Analysis Toxicity Description High,,text,Hypermagnesemia,,,,13,,
ATOXDSH,Analysis Toxicity Description High,,text,Hypernatremia,,,,14,,
ATOXDSH,Analysis Toxicity Description High,,text,Eosinophilia,,,,15,,
ATOXDSH,Analysis Toxicity Description High,,text,Hemoglobin increased,,,,16,,
ATOXDSH,Analysis Toxicity Description High,,text,Lymphocyte count increased,,,,17,,
ATOXDSH,Analysis Toxicity Description High,,text,Leukocytosis,,,,18,,
ATOXDSL,Analysis Toxicity Description Low,,text,Hypoalbuminemia,,,,1,,
ATOXDSL,Analysis Toxicity Description Low,,text,Hypocalcemia,,,,3,,
ATOXDSL,Analysis Toxicity Description Low,,text,Hypoglycemia,,,,4,,
ATOXDSL,Analysis Toxicity Description Low,,text,Hypokalemia,,,,5,,
ATOXDSL,Analysis Toxicity Description Low,,text,Hypomagnesemia,,,,6,,
ATOXDSL,Analysis Toxicity Description Low,,text,Hyponatremia,,,,7,,
ATOXDSL,Analysis Toxicity Description Low,,text,Hypophosphatemia,,,,,,
ATOXDSL,Analysis Toxicity Description Low,,text,Anemia,,,,8,,
ATOXDSL,Analysis Toxicity Description Low,,text,Lymphocytes decreased,,,,9,,
ATOXDSL,Analysis Toxicity Description Low,,text,Neutrophils (ANC) decreased,,,,10,,
ATOXDSL,Analysis Toxicity Description Low,,text,Platelets decreased,,,,11,,
ATOXDSL,Analysis Toxicity Description Low,,text,Leukopenia,,,,12,,
ATOXGR,Analysis Toxicity Grading,,text,Grade 0,,,0,0,,
ATOXGR,Analysis Toxicity Grading,,text,Grade 1,,,1,1,,
ATOXGR,Analysis Toxicity Grading,,text,Grade 2,,,2,2,,
ATOXGR,Analysis Toxicity Grading,,text,Grade 3,,,3,3,,
ATOXGR,Analysis Toxicity Grading,,text,Grade 4,,,4,4,,
CMACAT,Con Med Analysis Categories,,text,Con Med,,Prior and Concomitant Medications,,1,,
CMACAT,Con Med Analysis Categories,,text,Prior ACT,,History of Anti-Cancer Therapies,,2,,
CMACAT,Con Med Analysis Categories,,text,Subq ACT,,Concomitant and Subsequent Anti-Cancer Therapies,,3,,
CMCAT,Concomitant Medication Categories,,text,PRIOR AND CONCOMITANT MEDICATIONS,,,,1,,
CMCAT,Concomitant Medication Categories,,text,HISTORY OF ANTI-CANCER THERAPIES,,,,2,,
CMCAT,Concomitant Medication Categories,,text,CONCOMITANT AND SUBSEQUENT ANTI-CANCER THERAPIES,,,,3,,
CMINDTYP,Concomitant Medication Indication Type,,text,MEDICAL HISTORY,,,,1,,
CMINDTYP,Concomitant Medication Indication Type,,text,ADVERSE EVENT,,,,2,,
CMINDTYP,Concomitant Medication Indication Type,,text,PROPHYLAXIS,,,,3,,
CMREAS,Reason for discontinuation of regimen,,text,OTHER,,Other,,1,,
CMREAS,Reason for discontinuation of regimen,,text,COMPLETION OF THERAPY,,Completion of Therapy,,2,,
CMREAS,Reason for discontinuation of regimen,,text,ADVERSE EVENT,,Adverse Event,,3,,
CMREAS,Reason for discontinuation of regimen,,text,PROGRESSIVE DISEASE,,Progressive Disease,,4,,
CMROUTE,Medication Route,,text,SUBCUTANEOUS,,SC,,1,,
CMROUTE,Medication Route,,text,TRANSDERMAL,,Transdermal,,2,,
CMROUTE,Medication Route,,text,INTRAPERITONEAL,,IP,,3,,
CMROUTE,Medication Route,,text,TOPICAL,,Topical,,4,,
CMROUTE,Medication Route,,text,INTRAMUSCULAR,,IM,,5,,
CMROUTE,Medication Route,,text,INTRAVENOUS,,IV,,6,,
CMROUTE,Medication Route,,text,OTHER,,Other,,7,,
CMROUTE,Medication Route,,text,ORAL,,Oral,,8,,
CMSCAT,Concomitant Medication Sub-Category,,text,LOCAL,,Local,,1,,
CMSCAT,Concomitant Medication Sub-Category,,text,SYSTEMIC,,Systemic,,2,,
CMSCAT,Concomitant Medication Sub-Category,,text,OTHER,,Other,,3,,
CMSCAT,Concomitant Medication Sub-Category,,text,UNKNOWN,,Unknown,,4,,
CMTRTSTT,Treatment Setting,,text,METASTATIC,,,,1,,
CMTRTSTT,Treatment Setting,,text,NEOADJUVANT,,,,2,,
CMTRTSTT,Treatment Setting,,text,OTHER,,,,3,,
CMTRTSTT,Treatment Setting,,text,ADJUVANT,,,,4,,
CMTRTSTT,Treatment Setting,,text,LOCALLY ADVANCED,,,,5,,
COUNTRY,Country,,text,AUS,,Australia,,1,,
COUNTRY,Country,,text,BEL,,Belgium,,2,,
COUNTRY,Country,,text,FRA,,France,,3,,
COUNTRY,Country,,text,DEU,,Germany,,4,,
COUNTRY,Country,,text,HKG,,Hong Kong,,5,,
COUNTRY,Country,,text,HUN,,Hungary,,6,,
COUNTRY,Country,,text,NZL,,New Zealand,,7,,
COUNTRY,Country,,text,POL,,Poland,,8,,
COUNTRY,Country,,text,PRT,,Portugal,,9,,
COUNTRY,Country,,text,SGP,,Singapore,,10,,
COUNTRY,Country,,text,KOR,,"
South Korea",,11,,
COUNTRY,Country,,text,ESP,,Spain,,12,,
COUNTRY,Country,,text,TWN,,Taiwan,,13,,
COUNTRY,Country,,text,THA,,Thailand,,14,,
COUNTRY,Country,,text,GBR,,United Kingdom,,15,,
COUNTRY,Country,,text,USA,,United States of America,,16,,
DATEFL,Date Imputation Flag,C81223,text,D,C81212,Day is imputed.,,1,,
DATEFL,Date Imputation Flag,C81223,text,M,C81211,Month and day are imputed.,,2,,
DATEFL,Date Imputation Flag,C81223,text,Y,C81210,Entire date is imputed.,,3,,
DCRREAS,Radiographic FU Termination Reason,,text,PROGRESSIVE DISEASE,,Radiographic progression,1,1,,
DCRREAS,Radiographic FU Termination Reason,,text,NO LONGER CLINICALLY BENEFITING,,Clinical deterioration,2,2,,
DCRREAS,Radiographic FU Termination Reason,,text,COMPLETED,,Completed per protocol,3,3,,
DCRREAS,Radiographic FU Termination Reason,,text,WITHDRAWAL BY SUBJECT,,Withdrew consent,4,4,,
DCRREAS,Radiographic FU Termination Reason,,text,LOST TO FOLLOW-UP,,Lost to follow-up,5,5,,
DCRREAS,Radiographic FU Termination Reason,,text,DEATH,,Death,6,6,,
DCRREAS,Radiographic FU Termination Reason,,text,OTHER,,Other,7,7,,
DCRREAS,Radiographic FU Termination Reason,,text,,,Missing/ data not yet received,8,8,,
DCSREAS,Study Termination Reason,,text,DEATH,,Death,1,1,,
DCSREAS,Study Termination Reason,,text,WITHDRAWAL BY SUBJECT,,Withdrew consent,2,2,,
DCSREAS,Study Termination Reason,,text,LOST TO FOLLOW-UP,,Lost to follow-up,3,3,,
DCSREAS,Study Termination Reason,,text,SPONSOR REQUEST,,Sponsor decision,4,4,,
DCSREAS,Study Termination Reason,,text,OTHER,,Other,5,5,,
DCSREAS,Study Termination Reason,,text,,,Missing/ data not yet received,6,6,,
DCTREAS,Treatment Termination Reason,,text,PROGRESSIVE DISEASE,,Radiographic progression,1,1,,
DCTREAS,Treatment Termination Reason,,text,ADVERSE EVENT,,Adverse event,2,2,,
DCTREAS,Treatment Termination Reason,,text,LACK OF CLINICAL BENEFIT,,Lack of clinical benefit,3,3,,
DCTREAS,Treatment Termination Reason,,text,WITHDRAWAL BY SUBJECT,,Withdrew consent,4,4,,
DCTREAS,Treatment Termination Reason,,text,LOST TO FOLLOW-UP,,Lost to follow-up,5,5,,
DCTREAS,Treatment Termination Reason,,text,PROTOCOL DEVIATION,,Protocol deviation,6,6,,
DCTREAS,Treatment Termination Reason,,text,SPONSOR REQUEST,,Sponsor decision,7,7,,
DCTREAS,Treatment Termination Reason,,text,SUBJECT REQUEST,,Subject request,8,8,,
DCTREAS,Treatment Termination Reason,,text,COMPLETED,,Completed Study Treatment,9,9,,
DCTREAS,Treatment Termination Reason,,text,OTHER,,Other,10,10,,
DCTREAS,Treatment Termination Reason,,text,,,Missing/ data not yet received,11,11,,
DTHPER,Death Period (30 Days),,text,<= 30 days,,,,1,,
DTHPER,Death Period (30 Days),,text,> 30 days,,,,2,,
DTHPER2,Death Period (100 Days),,text,<= 135 days,,,,1,,
DTHPER2,Death Period (100 Days),,text,> 135 days,,,,2,,
DTHPER3,Death Period (100 Days),,text,<= 100 days,,,,,,
DTHPER3,Death Period (100 Days),,text,> 100 days,,,,,,
DTYPLB,Derivation Type for ADLB,,text,ULOQ,,Upper Limit of Quantification,,2,,
DTYPLB,Derivation Type for ADLB,,text,LLOQ,,Lower Limit of Quantification,,1,,
ECADJ,Reason for Dose Adjustment,,text,PERMANENT TREATMENT DISCONTINUATION,,,,1,,
ECADJ,Reason for Dose Adjustment,,text,ADVERSE EVENT,,,,2,,
ECADJ,Reason for Dose Adjustment,,text,SUBJECT NON-COMPLIANCE OTHER THAN AE,,,,3,,
ECADJ,Reason for Dose Adjustment,,text,SITE/LOGISTICAL ERROR,,,,4,,
ECADJ,Reason for Dose Adjustment,,text,TREATMENT RESUMED/RE-ESCALATED,,,,5,,
ECADJ,Reason for Dose Adjustment,,text,TREATMENT CYCLE COMPLETED,,,,6,,
ECADJ,Reason for Dose Adjustment,,text,OTHER,,,,7,,
ECDOSU,Dose Unit,C71620,text,mg,C28253,,,1,,
ECDOSFRM,Dose Form,C66726,text,INFUSION,C42946,,,1,,
ECDOSFRM,Dose Form,C66726,text,TABLET,C42998,,,2,,
ECDOSFRQ,Dosing Frequency per Interval,C71113,text,Q3W,C64535,Every 3 weeks,,1,,
ECDOSFRQ,Dosing Frequency per Interval,C71113,text,Q4W,,Every 4 weeks,,2,,
ECDOSFRQ,Dosing Frequency per Interval,C71113,text,QOD,,Every other day,,4,,
ECDOSFRQ,Dosing Frequency per Interval,C71113,text,QD,C25473,Daily,,2,,
ECROUTE,Route of Administration,C66729,text,ORAL,C38288,,,1,,
ECROUTE,Route of Administration,C66729,text,INTRAVENOUS,C38276,,,2,,
ECTRT,Treatment,,text,Nivolumab,,Nivolumab,,1,,
ECTRT,Treatment,,text,XL092,,XL092,,2,,
ECTRT,Treatment,,text,Ipilimumab,,Ipilimumab,,3,,
ECTRT,Treatment,,text,Relatlimab,,Relatlimab,,4,,
ENTPT,Relation to Reference Period,C66728,text,ONGOING,C53279,,,1,,
ETHNIC,Ethnicity,C66790,text,HISPANIC OR LATINO,C17459,Hispanic or Latino,,1,,
ETHNIC,Ethnicity,C66790,text,NOT HISPANIC OR LATINO,C41222,Not Hispanic or Latino,,2,,
ETHNIC,Ethnicity,C66790,text,NOT REPORTED,C43234,Not Reported,,3,,
LBSPEC,Lab Specimen Type,C78734,text,PLASMA,C13356,,,2,,
LBSPEC,Lab Specimen Type,C78734,text,BLOOD,C12434,,,1,,
LBSPEC,Lab Specimen Type,C78734,text,SERUM,C13325,,,3,,
LBSPEC,Lab Specimen Type,C78734,text,URINE,C13283,,,4,,
LBP1CAT,ADLB Parameter Category 1,,text,CHEMISTRY,,,,1,,
LBP1CAT,ADLB Parameter Category 1,,text,COAGULATION,,,,2,,
LBP1CAT,ADLB Parameter Category 1,,text,HEMATOLOGY,,,,3,,
LBP1CAT,ADLB Parameter Category 1,,text,PREGNANCY,,,,4,,
LBP1CAT,ADLB Parameter Category 1,,text,TUMOR MARKER,,,,5,,
LBP1CAT,ADLB Parameter Category 1,,text,URINE CHEMISTRY,,,,6,,
LBP1CAT,ADLB Parameter Category 1,,text,URINE CHEMISTRY - 24 HOUR,,,,7,,
MMRSTAT,MMR Status,,text,MMR PROFICIENT,,MMR proficient,,1,,
MMRSTAT,MMR Status,,text,MMR DEFICIENT,,MMR deficient,,2,,
MMRSTAT,MMR Status,,text,UNKNOWN,,Unknown,,3,,
MSICAT,MSI Status Category,,text,MSI-Low/MSS,,,,1,,
MSICAT,MSI Status Category,,text,MSI-High,,,,2,,
MSICAT,MSI Status Category,,text,Unknown,,,,3,,
MSISTAT,MSI Status,,text,MSS,,MSS,,1,,
MSISTAT,MSI Status,,text,MSI-LOW,,MSI-Low,,2,,
MSISTAT,MSI Status,,text,MSI-HIGH,,MSI-High,,3,,
MSISTAT,MSI Status,,text,UNKNOWN,,Unknown,,4,,
NRIND,Reference Range Indicator,C78736,text,HIGH,C78800,,,1,,
NRIND,Reference Range Indicator,C78736,text,LOW,C78801,,,2,,
NRIND,Reference Range Indicator,C78736,text,NORMAL,C78727,,,3,,
NY,No Yes Response,C66742,text,Y,C49488,Yes,,1,,
NY,No Yes Response,C66742,text,N,C49487,No,,2,,
NYU,No Yes Unknown Response,C66742,text,Y,C49488,Yes,,1,,
NYU,No Yes Unknown Response,C66742,text,N,C49487,No,,2,,
NYU,No Yes Unknown Response,C66742,text,U,C17998,Unknown,,3,,
PARBASE,ADBASE Parameters,,text,BONEDXYN,,Bone-Only Disease,1,1,,
PARBASE,ADBASE Parameters,,text,BRMYN,,Brain\cranial Metastases Present?,2,2,,
PARBASE,ADBASE Parameters,,text,CDHSFP,,Percentage of Sarcomatoid Feature,3,3,,
PARBASE,ADBASE Parameters,,text,CDHSFYN,,Sarcomatoid Feature,4,4,,
PARBASE,ADBASE Parameters,,text,CHDTC,,Date/Time of Initial Diagnosis,5,5,,
PARBASE,ADBASE Parameters,,text,CHSTAGE,,Current Disease Stage / Cancer Stage,6,6,,
PARBASE,ADBASE Parameters,,text,DIAGDURY,,Duration from Initial Diagnosis to First Dose (years),7,7,,
PARBASE,ADBASE Parameters,,text,HISTSP,,"Histology Other, Specify",8,8,,
PARBASE,ADBASE Parameters,,text,HISTTYPC,,Histology Type,9,9,,
PARBASE,ADBASE Parameters,,text,IMDCPSC,,IMDC Prognostic Score,10,10,,
PARBASE,ADBASE Parameters,,text,LDRPDDTC,,Date of Recurrence/Progression,11,11,,
PARBASE,ADBASE Parameters,,text,MCRPCDTC,,Date/Time of Diagnosis of MCRPC,12,12,,
PARBASE,ADBASE Parameters,,text,NSITEBL,,Num Non-Target Tumor Sites at BL,13,13,,
PARBASE,ADBASE Parameters,,text,NTSITEBL,,Num Target Tumor Sites at BL,14,14,,
PARBASE,ADBASE Parameters,,text,PACTLINE,,Prior Lines of Therapy,15,15,,
PARBASE,ADBASE Parameters,,text,PACYN,,Diagnosed with Prostate Adenocarcinoma,16,16,,
PARBASE,ADBASE Parameters,,text,PCTTOTRT,,Time from End PACT to Treatment Start,17,17,,
PARBASE,ADBASE Parameters,,text,PDL1YN,,Previous Immune Checkpoint Inhibitor,18,18,,
PARBASE,ADBASE Parameters,,text,PDTOTRT,,Time from PD on PACT to Treatment Start,19,19,,
PARBASE,ADBASE Parameters,,text,PRGLSC,,Primary Gleason Score at Diagnosis,20,20,,
PARBASE,ADBASE Parameters,,text,PSAPDYN,,PSA Progression at Screening,21,21,,
PARBASE,ADBASE Parameters,,text,RGNUM,,Number of Prior Anti-Cancer Regimens,22,22,,
PARBASE,ADBASE Parameters,,text,RNLPRYN,,Nephrectomy Performed,23,23,,
PARBASE,ADBASE Parameters,,text,SEGLSC,,Secondary Gleason Score at Diagnosis,24,24,,
PARBASE,ADBASE Parameters,,text,STPDYN,,Soft Tissue PD at Screening,25,25,,
PARBASE,ADBASE Parameters,,text,SUBTUMOR,,Tumor Sub Type,26,26,,
PARBASE,ADBASE Parameters,,text,TOTGLSC,,Total Gleason Score,27,27,,
PARBASE,ADBASE Parameters,,text,TSITEBL,,Num of Tumor Sites at BL,28,28,,
PARBASE,ADBASE Parameters,,text,TUMOR,,Pathological Diagnosis Tumor Type,29,29,,
PARBASE,ADBASE Parameters,,text,TUMORSP,,"Tumor Other, Specify",30,30,,
PARCH,ADCH Parameters,,text,BONEDXYN ,,Bone-Only Disease ,1,1,,"ML 03/30/2023: Codelist is incorrect for 092-002 study. Please update as per the study.
MS 04/03/2023: Updated"
PARCH,ADCH Parameters,,text,BRMYN    ,,Brain\cranial Metastases Present? ,2,2,,
PARCH,ADCH Parameters,,text,CDHSFYN  ,,Sarcomatoid Feature ,3,3,,
PARCH,ADCH Parameters,,text,CHDTC    ,,Date/Time of Initial Diagnosis ,4,4,,
PARCH,ADCH Parameters,,text,HISTSP   ,,"Histology Other, Specify ",5,5,,
PARCH,ADCH Parameters,,text,HISTTYPC ,,Histology Type ,6,6,,
PARCH,ADCH Parameters,,text,IMDCPSC  ,,IMDC Prognostic Score ,7,7,,
PARCH,ADCH Parameters,,text,LDRPDDTC ,,Date of Recurrence/Progression ,8,8,,
PARCH,ADCH Parameters,,text,MCRPCDTC ,,Date/Time of Diagnosis of MCRPC ,9,9,,
PARCH,ADCH Parameters,,text,PACYN   ,,Diagnosed with Prostate Adenocarcinoma ,10,10,,
PARCH,ADCH Parameters,,text,PRGLSC  ,,Primary Gleason Score at Diagnosis ,11,11,,
PARCH,ADCH Parameters,,text,PSAPDYN ,,PSA Progression at Screening ,12,12,,
PARCH,ADCH Parameters,,text,RNLPRYN ,,Nephrectomy Performed ,13,13,,
PARCH,ADCH Parameters,,text,SEGLSC  ,,Secondary Gleason Score at Diagnosis ,14,14,,
PARCH,ADCH Parameters,,text,STAGE   ,,Current Disease Stage / Cancer Stage ,15,15,,
PARCH,ADCH Parameters,,text,STPDYN  ,,Soft Tissue PD at Screening ,16,16,,
PARCH,ADCH Parameters,,text,SUBTUMOR,,Tumor Sub Type ,17,17,,
PARCH,ADCH Parameters,,text,TOTGLSC ,,Total Gleason Score ,18,18,,
PARCH,ADCH Parameters,,text,TUMOR   ,,Pathological Diagnosis Tumor Type ,19,19,,
PARCH,ADCH Parameters,,text,TUMORSP ,,"Tumor Other, Specify ",20,20,,
PARCH,ADCH Parameters,,text,CDHSFP,,Percentage of Sarcomatoid Feature,21,21,,
PARCH,ADCH Parameters,,text,PDL1YN,,Previous Immune Checkpoint Inhibitor,22,22,,
PAREX,ADEX Parameters,,text,TDDOSE,,Total Daily Dose (mg),1,1,,
PAREXS,ADEXSUM Parameters,,text,XLTRDURD,,Duration of Exposure for XL092 (Days),1,1,,
PAREXS,ADEXSUM Parameters,,text,XLTRDURM,,Duration of Exposure for XL092 (Months),2,2,,
PAREXS,ADEXSUM Parameters,,text,XLCUMDOS,,Cumulative Dose of XL092 (mg),3,3,,
PAREXS,ADEXSUM Parameters,,text,XLDOSAVG,,Average Daily Dose of XL092 (mg/day),4,4,,
PAREXS,ADEXSUM Parameters,,text,XLDOSINT,,Percent Dose Intensity for XL092 (%),5,5,,
PAREXS,ADEXSUM Parameters,,text,DURTDH,,Duration of Total Dose Hold (Days),6,6,,
PAREXS,ADEXSUM Parameters,,text,DUREHLD,,Duration of Exp Exc. Dose Hold (Months),7,7,,
PAREXS,ADEXSUM Parameters,,text,XLADINT,,Actual Dose Int XL092 (mg/week),8,8,,
PAREXS,ADEXSUM Parameters,,text,XAEREDS,,Number of AE Dose Reductions for XL093,9,9,,
PAREXS,ADEXSUM Parameters,,text,XNDOSRED,,Number of Dose Reductions for XL093,10,10,,
PAREXS,ADEXSUM Parameters,,text,XTT1RED,,Time to 1st Dose Red for XL092 (Days),11,11,,
PAREXS,ADEXSUM Parameters,,text,XAEHLDS,,Number of AE Dose Holds for XL093,12,12,,
PAREXS,ADEXSUM Parameters,,text,XNDOSHLD,,Number of Dose Holds for XL093,13,13,,
PAREXS,ADEXSUM Parameters,,text,XTT1HLD,,Time to 1st Dose Hold for XL092 (Days),14,14,,
PAREXS,ADEXSUM Parameters,,text,NMODANYX,,Number of Any XL092 Dose Mods ,15,15,,
PAREXS,ADEXSUM Parameters,,text,NMODAEX,,Number of Any XL092 Dose Mods due to AE,16,16,,
PAREXS,ADEXSUM Parameters,,text,XTTFMOD,,Time to 1st XL092 Dose AE Mod (Days),17,17,,
PAREXS,ADEXSUM Parameters,,text,LOWDOSE,,Lowest Non-zero Dose Received,18,18,,
PAREXS,ADEXSUM Parameters,,text,TT1HLD07,,Time to 1st 7 day AE Dose Hold (Days),19,19,,
PAREXS,ADEXSUM Parameters,,text,TT1HLD14,,Time to 1st 14 day AE Dose Hold (Days),20,20,,
PAREXS,ADEXSUM Parameters,,text,TT1HLD21,,Time to 1st 21 day AE Dose Hold (Days),21,21,,
PAREXS,ADEXSUM Parameters,,text,NVTRDURD,,Duration of Exposure for Nivolumab (Days),22,22,,
PAREXS,ADEXSUM Parameters,,text,NVTRDURM,,Duration of Exposure for Nivolumab (Months),23,23,,
PAREXS,ADEXSUM Parameters,,text,NVCUMDOS,,Cumulative Dose of Nivolumab (mg),24,24,,
PAREXS,ADEXSUM Parameters,,text,NVNUMINF,,Number of Infusions of Nivolumab ,25,25,,
PAREXS,ADEXSUM Parameters,,text,NVNEXINF,,Number of Expected Infusions of Nivolumab ,26,26,,
PAREXS,ADEXSUM Parameters,,text,NVEXCDOS,,Cumulative Expected Dose for Nivolumab (mg),27,27,,
PAREXS,ADEXSUM Parameters,,text,NVDOSINT,,Percent Dose Intensity For Nivolumab (%),28,28,,
PAREXS,ADEXSUM Parameters,,text,NVADINT,,Actual Dose Int Nivolumab (mg/week),29,29,,
PAREXS,ADEXSUM Parameters,,text,NAEREDS,,Number of AE Dose Reductions for Nivo,30,30,,
PAREXS,ADEXSUM Parameters,,text,NNDOSRED,,Number of Dose Reductions for Nivo,31,31,,
PAREXS,ADEXSUM Parameters,,text,NTT1RED,,Time to 1st Dose Red for Nivo (Days),32,32,,
PAREXS,ADEXSUM Parameters,,text,NAEHLDS,,Number of AE Dose Holds for Nivo,33,33,,
PAREXS,ADEXSUM Parameters,,text,NNDOSHLD,,Number of Dose Holds for Nivo,34,34,,
PAREXS,ADEXSUM Parameters,,text,NTT1HLD,,Time to 1st Dose Hold for Nivo (Days),35,35,,
PAREXS,ADEXSUM Parameters,,text,NMODANYN,,Number of Any Nivo Dose Mods ,36,36,,
PAREXS,ADEXSUM Parameters,,text,NMODAEN,,Number of Any Nivo Dose Mods due to AE,37,37,,
PAREXS,ADEXSUM Parameters,,text,NTTFMOD,,Time to 1st Nivo Dose AE Mod (Days),38,38,,
PAREXS,ADEXSUM Parameters,,text,IPTRDURD,,Duration of Exposure for Ipilimumab (Days),39,39,,
PAREXS,ADEXSUM Parameters,,text,IPTRDURM,,Duration of Exposure for Ipilimumab (Months),40,40,,
PAREXS,ADEXSUM Parameters,,text,IPCUMDOS,,Cumulative Dose of Ipilimumab (mg),41,41,,
PAREXS,ADEXSUM Parameters,,text,IPNUMINF,,Number of Infusions of Ipilimumab ,42,42,,
PAREXS,ADEXSUM Parameters,,text,IPDOSAVG,,Average dose per Infusion Ipilimumab (mg/infusion) ,43,43,,
PAREXS,ADEXSUM Parameters,,text,IPDOSINT,,Percent Dose Intensity For Ipilimumab (%),44,44,,
PAREXS,ADEXSUM Parameters,,text,IAEREDS,,Number of AE Dose Reductions for Ipi,45,45,,
PAREXS,ADEXSUM Parameters,,text,INDOSRED,,Number of Dose Reductions for Ipi,46,46,,
PAREXS,ADEXSUM Parameters,,text,ITT1RED,,Time to 1st Dose Red for Ipi (Days),47,47,,
PAREXS,ADEXSUM Parameters,,text,IAEHLDS,,Number of AE Dose Holds for Ipi,48,48,,
PAREXS,ADEXSUM Parameters,,text,INDOSHLD,,Number of Dose Holds for Ipi,49,49,,
PAREXS,ADEXSUM Parameters,,text,ITT1HLD,,Time to 1st Dose Hold for Ipi (Days),50,50,,
PAREXS,ADEXSUM Parameters,,text,NMODANYI,,Number of Any Ipi Dose Mods ,51,51,,
PAREXS,ADEXSUM Parameters,,text,NMODAEI,,Number of Any Ipi Dose Mods due to AE,52,52,,
PAREXS,ADEXSUM Parameters,,text,ITTFMOD,,Time to 1st Ipi Dose AE Mod (Days),53,53,,
PAREXS,ADEXSUM Parameters,,text,IADINT,,Actual Dose Int Ipilimumab (mg/week),54,54,,
PAREXS,ADEXSUM Parameters,,text,INEXINF,,Number of Expected Infusions of Ipi ,55,55,,
PAREXS,ADEXSUM Parameters,,text,IEXCDOS,,Cumulative Expected Dose for Ipi (mg),56,56,,
PAREXS,ADEXSUM Parameters,,text,RLTRDURD,,Duration of Exposure for Nivo/Rela FDC (Days),57,57,,
PAREXS,ADEXSUM Parameters,,text,RLTRDURM,,Duration of Exposure for Nivo/Rela FDC (Months),58,58,,
PAREXS,ADEXSUM Parameters,,text,RLCUMDOS,,Cumulative Dose of Nivo/Rela FDC (mg),59,59,,
PAREXS,ADEXSUM Parameters,,text,RLNUMINF,,Number of Infusions of Nivo/Rela FDC ,60,60,,
PAREXS,ADEXSUM Parameters,,text,RLDOSAVG,,Average dose per Infusion Nivo/Rela FDC (mg/infusion) ,61,61,,
PAREXS,ADEXSUM Parameters,,text,RLNEXINF,,Number of Expected Infusions of Nivo/Rela FDC ,62,62,,
PAREXS,ADEXSUM Parameters,,text,RLEXCDOS,,Cumulative Expected Dose for Nivo/Rela FDC (mg),63,63,,
PAREXS,ADEXSUM Parameters,,text,RLDOSINT,,Percent Dose Intensity For Nivo/Rela FDC (%),64,64,,
PAREXS,ADEXSUM Parameters,,text,RAEREDS,,Number of AE Dose Reductions for Nivo/Rela FDC,65,65,,
PAREXS,ADEXSUM Parameters,,text,RNDOSRED,,Number of Dose Reductions for Nivo/Rela FDC,66,66,,
PAREXS,ADEXSUM Parameters,,text,RTT1RED,,Time to 1st Dose Red for Nivo/Rela FDC (Days),67,67,,
PAREXS,ADEXSUM Parameters,,text,RAEHLDS,,Number of AE Dose Holds for Nivo/Rela FDC,68,68,,
PAREXS,ADEXSUM Parameters,,text,RNDOSHLD,,Number of Dose Holds for Nivo/Rela FDC,69,69,,
PAREXS,ADEXSUM Parameters,,text,RTT1HLD,,Time to 1st Dose Hold for Nivo/Rela FDC (Days),70,70,,
PAREXS,ADEXSUM Parameters,,text,NMODANYR,,Number of Any Rela Dose Mods ,71,71,,
PAREXS,ADEXSUM Parameters,,text,NMODAER,,Number of Any Rela Dose Mods due to AE,72,72,,
PAREXS,ADEXSUM Parameters,,text,RTTFMOD,,Time to 1st Rela Dose AE Mod (Days),73,73,,
PAREXS,ADEXSUM Parameters,,text,RADINT,,Actual Dose Int Relatlimab (mg/week),74,74,,
PAREXS,ADEXSUM Parameters,,text,HLDAEDUR,,Duration of Dose Holds Due to AE,75,75,,
PAREXS,ADEXSUM Parameters,,text,TOTHLDAE,,Total Duration of Dose Holds Due to AE,76,76,,
PAREXS,ADEXSUM Parameters,,text,TOTDURN,,Total Duration of Any Treatment (Months),77,77,,
PAREXS,ADEXSUM Parameters,,text,NVDOSAVG,,Average dose per Inf Nivo (mg/infusion),78,78,,
PARLB,ADLB Parameters,C65047,text,ALB,C64431,Albumin (g/L),1,1,,
PARLB,ADLB Parameters,C65047,text,ALP,C64432,Alkaline Phosphatase (U/L),2,2,,
PARLB,ADLB Parameters,C65047,text,ALT,C64433,Alanine Aminotransferase (U/L),3,3,,
PARLB,ADLB Parameters,C65047,text,AST,C64467,Aspartate Aminotransferase (U/L),4,4,,
PARLB,ADLB Parameters,C65047,text,AMYLASE,C64434,Amylase (U/L),5,5,,
PARLB,ADLB Parameters,C65047,text,BICARB,C74667,Bicarbonate (mmol/L),6,6,,
PARLB,ADLB Parameters,C65047,text,BILI,C38037,Bilirubin (umol/L),7,7,Amylase (U/L),
PARLB,ADLB Parameters,C65047,text,CA,C64488,Calcium (mmol/L),8,8,,
PARLB,ADLB Parameters,C65047,text,CACR,C119272,Calcium Corrected (mmol/L),9,9,,
PARLB,ADLB Parameters,C65047,text,CL,C64495,Chloride (mmol/L),10,10,,
PARLB,ADLB Parameters,C65047,text,CREAT,C64547,Creatinine (umol/L),11,11,,
PARLB,ADLB Parameters,C65047,text,CREATCLR,C64547,Creatinine Clearance (mL/sec),12,12,,
PARLB,ADLB Parameters,C65047,text,GGT,C64847,Gamma Glutamyl Transferase (U/L),13,13,,
PARLB,ADLB Parameters,C65047,text,GLUC,C105585,Glucose (mmol/L),14,14,,
PARLB,ADLB Parameters,C65047,text,K,C64853,Potassium (mmol/L),15,15,,
PARLB,ADLB Parameters,C65047,text,LDH,C64855,Lactate Dehydrogenase (U/L),16,16,,
PARLB,ADLB Parameters,C65047,text,LIPASET,C117748,Lipase (U/L),17,17,,
PARLB,ADLB Parameters,C65047,text,MG,C64840,Magnesium (mmol/L),18,18,,
PARLB,ADLB Parameters,C65047,text,PHOS,C64857,Phosphate (mmol/L),19,19,,
PARLB,ADLB Parameters,C65047,text,PROT,C64858,Protein (g/L),20,20,,
PARLB,ADLB Parameters,C65047,text,SODIUM,C64809,Sodium (mmol/L),21,21,,
PARLB,ADLB Parameters,C65047,text,T4,C74794,Thyroxine (nmol/L),22,22,,
PARLB,ADLB Parameters,C65047,text,T4FR,C74786,"Thyroxine, Free (pmol/L)",23,23,,
PARLB,ADLB Parameters,C65047,text,TSH,C64813,Thyrotropin (mIU/L),24,24,,
PARLB,ADLB Parameters,C65047,text,UREAN,C125949,Urea Nitrogen (mmol/L),25,25,,
PARLB,ADLB Parameters,C65047,text,RBC,C51946,Erythrocytes (TI/L),30,26,,
PARLB,ADLB Parameters,C65047,text,HGB,C64848,Hemoglobin (g/L),31,27,,
PARLB,ADLB Parameters,C65047,text,HCT,C64796,Hematocrit (fraction of 1),32,28,,
PARLB,ADLB Parameters,C65047,text,PLAT,C51951,Platelets (GI/L),33,29,,
PARLB,ADLB Parameters,C65047,text,WBC,C51948,Leukocytes (GI/L),34,30,,
PARLB,ADLB Parameters,C65047,text,BASO,C64470,Basophils (GI/L),35,31,,
PARLB,ADLB Parameters,C65047,text,BASOLE,C64471,Basophils/Leukocytes (%),36,32,,
PARLB,ADLB Parameters,C65047,text,EOS,C64550,Eosinophils (GI/L),37,33,,
PARLB,ADLB Parameters,C65047,text,EOSLE,C64604,Eosinophils/Leukocytes (%),38,34,,
PARLB,ADLB Parameters,C65047,text,LYM,C51949,Lymphocytes (GI/L),39,35,,
PARLB,ADLB Parameters,C65047,text,LYMLE,C64820,Lymphocytes/Leukocytes (%),40,36,,
PARLB,ADLB Parameters,C65047,text,MONO,C64823,Monocytes (GI/L),41,37,,
PARLB,ADLB Parameters,C65047,text,MONOLE,C64824,Monocytes/Leukocytes (%),42,38,,
PARLB,ADLB Parameters,C65047,text,NEUT,C63321,Neutrophils (GI/L),43,39,,
PARLB,ADLB Parameters,C65047,text,NEUTLE,C64827,Neutrophils/Leukocytes (%),44,40,,
PARLB,ADLB Parameters,C65047,text,LEIM,C127625,Immature Leukocytes (GI/L),45,41,,
PARLB,ADLB Parameters,C65047,text,LEIMLE,C127626,Immature Leukocytes/Leukocytes (%),46,42,,
PARLB,ADLB Parameters,C65047,text,APTT,C38462,Activated Partial Thromboplastin Time (sec),50,43,,
PARLB,ADLB Parameters,C65047,text,INR,C64805,Prothrombin Intl. Normalized Ratio (RATIO),51,44,,
PARLB,ADLB Parameters,C65047,text,PT,C62656,Prothrombin Time (sec),52,45,,
PARLB,ADLB Parameters,C65047,text,CREATU,C64547,Urine Creatinine (mmol/L),60,46,,
PARLB,ADLB Parameters,C65047,text,PROTU,C64858,Urine Protein (mg/dL),61,47,,
PARLB,ADLB Parameters,C65047,text,PROTCRT,C79463,Urine Protein/Creatinine (mg/mmol),62,48,,
PARLB,ADLB Parameters,C65047,text,PROT24,,Protein in 24h,63,49,,
PARLB,ADLB Parameters,C65047,text,FSH,C74783,Follicle Stimulating Hormone (IU/L),70,50,,
PARLB,ADLB Parameters,C65047,text,CA19_9AG,C81982,Cancer Antigen 19-9 (U/mL),81,51,,
PARLB,ADLB Parameters,C65047,text,CEA,C81983,Carcinoembryonic Antigen (ug/L),82,52,,
PARLB,ADLB Parameters,C65047,text,CRP,,C Reactive Protein (mg/L),83,53,,
PARLB,ADLB Parameters,C65047,text,HBSAGQL,,"Hepatitis B Virus Surface Antigen, qual",84,54,,
PARLB,ADLB Parameters,C65047,text,HCABQL,,"Hepatitis C Virus Antibody, qual",85,55,,
PARLB,ADLB Parameters,C65047,text,LIPASE,,Triacylglycerol Lipase (U/L),86,56,,
PARLB,ADLB Parameters,C65047,text,MCH,,Ery. Mean Corpuscular Hemoglobin (pg),87,57,,
PARLB,ADLB Parameters,C65047,text,MCHC,,Ery. Mean Corpuscular Hemoglobin Concent (g/dL),88,58,,
PARLB,ADLB Parameters,C65047,text,MCV,,Ery. Mean Corpuscular Volume (fL),89,59,,
PARLB,ADLB Parameters,C65047,text,BILDIR,,Direct Bilirubin (umol/L),90,60,,
PARLB,ADLB Parameters,C65047,text,BILIND,,Indirect Bilirubin (umol/L),91,61,,
PARLB,ADLB Parameters,C65047,text,HCAB,,Hepatitis C Virus Antibody (RATIO),92,62,,
PARLB,ADLB Parameters,C65047,text,TROPONI,,Troponin I (ug/L),93,63,,
PARLB,ADLB Parameters,C65047,text,TROPIHS,,Troponin I High Sensitivity (ug/L),94,64,,
PARLB,ADLB Parameters,C65047,text,CK,,Creatine Kinase (U/L),95,65,,
PARLB,ADLB Parameters,C65047,text,PREGPOS,,Pregnancy Test,96,66,,
PARLB,ADLB Parameters,C65047,text,PSA,,Prostate Specific Antigen (ug/L),97,67,,
PARLB,ADLB Parameters,C65047,text,PSA1,,PSA Progression 1 (NG/ML),98,68,,
PARLB,ADLB Parameters,C65047,text,PSA2,,PSA Progression 2 (NG/ML),99,69,,
PARLB,ADLB Parameters,C65047,text,PSA3,,PSA Progression 3 (NG/ML),100,70,,
PARLB,ADLB Parameters,C65047,text,PSA4,,PSA Progression 4 (NG/ML),101,71,,
PARLB,ADLB Parameters,C65047,text,PTR,,Prothrombin Time Ratio,102,72,,
PARLB,ADLB Parameters,C65047,text,TESTOS,,Testosterone (nmol/L),103,73,,
PARLB,ADLB Parameters,C65047,text,CAION,,"Calcium, Ionized (mmol/L)",104,74,,
PARLB,ADLB Parameters,C65047,text,CRPHS,,C Reactive Protein High Sensitivity (mg/L),105,75,Update for duplicate with CRP,
PARLB,ADLB Parameters,C65047,text,HBSABQL,,"Hepatitis B Virus Surface Antibody, qual",106,76,,
PARLB,ADLB Parameters,C65047,text,NEUTB,,Neutrophils Band Form (GI/L),107,77,,
PARLB,ADLB Parameters,C65047,text,NEUTBLE,,Neutrophils Band Form/Leukocytes (%),108,78,,
PARLB,ADLB Parameters,C65047,text,NEUTSG,,"Neutrophils, Segmented (GI/L)",109,79,,
PARLB,ADLB Parameters,C65047,text,NEUTSGLE,,"Neutrophils, Segmented/Leukocytes (%)",110,80,,
PARLB,ADLB Parameters,C65047,text,TROPONT,,Troponin T (ug/L),111,81,,
PARLB,ADLB Parameters,C65047,text,TROPTHS,,Troponin T High Sensitivity (ug/L),112,82,,
PARLB,ADLB Parameters,C65047,text,HCRNAQL,,"Hepatitis C RNA, qual",113,83,,
PARLB,ADLB Parameters,C65047,text,APTTSTND,,Activated PTT/Standard (RATIO),114,84,,
PARLB,ADLB Parameters,C65047,text,ALPBS,,Bone Specific Alkaline Phosphatase (U/L),115,85,,
PARLB,ADLB Parameters,C65047,text,AMYLASEP,,"Amylase, Pancreatic (U/L)",116,86,,
PARLB,ADLB Parameters,C65047,text,HBSAG,,Hepatitis B Virus Surface Antigen,117,87,,
PARLB,ADLB Parameters,C65047,text,AFP,,Alpha Fetoprotein (ug/L),118,88,,
PARLB,ADLB Parameters,C65047,text,HBDNAQL,,"Hepatitis B DNA, qual",119,89,,
PARLB,ADLB Parameters,C65047,text,PSAP,,PSA Progression (NG/ML),120,90,,
PARLB,ADLB Parameters,C65047,text,HBSAB,,Hepatitis B Virus Surface Antibody (U/L),121,91,,
,,,,,,,,,,
,,,,,,,,,,
PRCAT,Procedure Category,,text,HISTORY OF LOCAL RADIATION THERAPY,,,,1,,
PRCAT,Procedure Category,,text,HISTORY OF SURGERIES AND PROCEDURES,,,,2,,
PRCAT,Procedure Category,,text,CONCOMITANT/SUBSEQUENT SURGERY AND PROCS,,,,3,,
PRCAT,Procedure Category,,text,IMAGING DETAILS,,,,4,,
PRCAT,Procedure Category,,text,PRIOR AND CONCOMITANT TRANSFUSIONS,,,,5,,
PRCAT,Procedure Category,,text,CONCOMITANT AND SUBSEQUENT LOCAL RADIATION THERAPY,,,,6,,
PROTVS,Protocol Version,,text,ORIGINAL,,,1,1,,
PROTVS,Protocol Version,,text,AMENDMENT 1.0,,,2,2,,
PRSITE,Procedure Site Type,,text,UNKNOWN,,,,1,,
PRSITE,Procedure Site Type,,text,SOFT TISSUE,,,,2,,
PRSITE,Procedure Site Type,,text,BONE,,,,3,,
RACE,Race,C74457,text,AMERICAN INDIAN OR ALASKA NATIVE,C41259,American Indian/Alaska Native,,1,,
RACE,Race,C74457,text,ASIAN,C41260,Asian,,2,,
RACE,Race,C74457,text,BLACK OR AFRICAN AMERICAN,C16352,Black/African American,,3,,
RACE,Race,C74457,text,NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER,C41219,Native Hawaiian or Other Pacific Islander,,4,,
RACE,Race,C74457,text,WHITE,C41261,White,,5,,
RACE,Race,C74457,text,MULTIPLE,,Multiple,,6,,
RACE,Race,C74457,text,OTHER,,Other,,7,,
RACE,Race,C74457,text,NOT REPORTED,,Not Reported,,8,,
RASSTAT,RAS Status,,text,Wild type,,,,1,,
RASSTAT,RAS Status,,text,Mutant,,,,2,,
RASSTAT2,RAS Status Mutations,,text,KRAS MUTATION,,KRAS mutation,,1,,
RASSTAT2,RAS Status Mutations,,text,NRAS  MUTATION,,NRAS mutation,,2,,
RASSTAT2,RAS Status Mutations,,text,RAS WILDTYPE,,RAS wildtype,,3,,
RASSTAT2,RAS Status Mutations,,text,UNKNOWN,,Unknown,,4,,
SBJTSTAT,Subject Trial Status,C124296,text,DISCONTINUED,C25484,Discontinued,,1,,
SBJTSTAT,Subject Trial Status,C124296,text,ONGOING,C53279,Ongoing,,2,,
SARCPCT,Sarcomatoid Feature Percentage,,text,< 50%,,,,1,,
SARCPCT,Sarcomatoid Feature Percentage,,text,>= 50%,,,,2,,
SARCPCT,Sarcomatoid Feature Percentage,,text,Unknown,,,,3,,
SEX,Sex,C66731,text,M,C20197,Male,,1,,
SEX,Sex,C66731,text,F,C16576,Female,,2,,
STAGE,Study Stage,,text,ESCALATION,,,,,,
STAGE,Study Stage,,text,EXPANSION,,,,,,
STAT,Completion Status,C66789,text,NOT DONE,C49484,,,,,
STRATAR,Strata used for Randomization,,text,liver:No|ras_status:Wild Type|region:Asia,,"Asia, Wild type, Liver metastasis = No",1,1,,
STRATAR,Strata used for Randomization,,text,liver:Yes|ras_status:Wild Type|region:Asia ,,"Asia, Wild type, Liver metastasis = Yes",2,2,,
STRATAR,Strata used for Randomization,,text,liver:No|ras_status:Mutant|region:Asia,,"Asia, Mutant, Liver metastasis = No",3,3,,
STRATAR,Strata used for Randomization,,text,liver:Yes|ras_status:Mutant|region:Asia,,"Asia, Mutant, Liver metastasis = Yes",4,4,,
STRATAR,Strata used for Randomization,,text,liver:No|ras_status:Wild Type|region:Other,,"Other, Wild type, Liver metastasis = No",5,5,,
STRATAR,Strata used for Randomization,,text,liver:Yes|ras_status:Wild Type|region:Other,,"Other, Wild type, Liver metastasis = Yes",6,6,,
STRATAR,Strata used for Randomization,,text,liver:No|ras_status:Mutant|region:Other,,"Other, Mutant, Liver metastasis = No",7,7,,
STRATAR,Strata used for Randomization,,text,liver:Yes|ras_status:Mutant|region:Other,,"Other, Mutant, Liver metastasis = Yes",8,8,,
SUSTAT,Substance Use Status,C78738,text,NEVER,C70543,Never user,,1,,
SUSTAT,Substance Use Status,C78738,text,FORMER,C25627,Former user,,2,,
SUSTAT,Substance Use Status,C78738,text,CURRENT,C25471,Current user,,3,,
TOXGRAE,Toxicity Grading (AEs),,text,0,,Grade 0,0,1,,
TOXGRAE,Toxicity Grading (AEs),,text,1,,Grade 1,1,2,,
TOXGRAE,Toxicity Grading (AEs),,text,2,,Grade 2,2,3,,
TOXGRAE,Toxicity Grading (AEs),,text,3,,Grade 3,3,4,,
TOXGRAE,Toxicity Grading (AEs),,text,4,,Grade 4,4,5,,
TOXGRAE,Toxicity Grading (AEs),,text,5,,Grade 5,5,6,,
TOXGRLB,Toxicity Grading (Labs),,text,0,,Grade 0,0,1,,
TOXGRLB,Toxicity Grading (Labs),,text,1,,Grade 1,1,2,,
TOXGRLB,Toxicity Grading (Labs),,text,2,,Grade 2,2,3,,
TOXGRLB,Toxicity Grading (Labs),,text,3,,Grade 3,3,4,,
TOXGRLB,Toxicity Grading (Labs),,text,4,,Grade 4,4,5,,
TRT01A,Actual Treatment for Period 01,,text,XL092 100 MG + NIVOLUMAB 360 MG,,,1,1,,
TRT01A,Actual Treatment for Period 01,,text,XL092 40 MG + NIVOLUMAB 3 MG/KG + IPILIMUMAB 1 MG/KG,,,2,2,,
TRT01A,Actual Treatment for Period 01,,text,XL092 60 MG + NIVOLUMAB 3 MG/KG + IPILIMUMAB 1 MG/KG,,,3,3,,
TRT01A,Actual Treatment for Period 01,,text,XL092 80 MG + NIVOLUMAB 3 MG/KG + IPILIMUMAB 1 MG/KG,,,4,4,,
TRT01A,Actual Treatment for Period 01,,text,XL092 100 MG,,,5,5,,
TRT01A,Actual Treatment for Period 01,,text,XL092 100 MG + NIVOLUMAB 480 MG,,,6,6,,
TRT01A,Actual Treatment for Period 01,,text,XL092 60 MG + NIVOLUMAB 480 MG + RELATLIMAB 480 MG,,,7,7,,
TRT01A,Actual Treatment for Period 01,,text,XL092 100 MG + NIVOLUMAB 480 MG + RELATLIMAB 480 MG,,,8,8,,
TRT01A,Actual Treatment for Period 01,,text,XL092 60 MG,,,9,9,,
TRT01A,Actual Treatment for Period 01,,text,"XL092 60 MG +
NIVOLUMAB 360 MG",,,10,10,,
TRT01A,Actual Treatment for Period 01,,text,"XL092 60 MG +
NIVOLUMAB 480 MG",,,11,11,,
TRT01A,Actual Treatment for Period 01,,text,Not Treated,,,99,12,,
TRT01P,Planned Treatment for Period 01,,text,XL092 100 MG + NIVOLUMAB 360 MG,,,1,1,,
TRT01P,Planned Treatment for Period 01,,text,XL092 40 MG + NIVOLUMAB 3 MG/KG + IPILIMUMAB 1 MG/KG,,,2,2,,
TRT01P,Planned Treatment for Period 01,,text,XL092 60 MG + NIVOLUMAB 3 MG/KG + IPILIMUMAB 1 MG/KG,,,3,3,,
TRT01P,Planned Treatment for Period 01,,text,XL092 80 MG + NIVOLUMAB 3 MG/KG + IPILIMUMAB 1 MG/KG,,,4,4,,
TRT01P,Planned Treatment for Period 01,,text,XL092 100 MG,,,5,5,,
TRT01P,Planned Treatment for Period 01,,text,XL092 100 MG + NIVOLUMAB 480 MG,,,6,6,,
TRT01P,Planned Treatment for Period 01,,text,XL092 60 MG + NIVOLUMAB 480 MG + RELATLIMAB 480 MG,,,7,7,,
TUHAND,Handedness of Primary Tumor,,text,Left-side,,,,1,,
TUHAND,Handedness of Primary Tumor,,text,Right-side,,,,2,,
TUHAND,Handedness of Primary Tumor,,text,Missing,,,,3,,
Y,No Yes Response (Y Subset),C66742,text,Y,C49488,Yes,,1,,
TRT01P,Planned Treatment for Period 01,,text,XL092 100 MG + NIVOLUMAB 480 MG + RELATLIMAB 480 MG,,,8,8,,
TRT01P,Planned Treatment for Period 01,,text,XL092 60 MG,,,9,9,,
TRT01P,Planned Treatment for Period 01,,text,"XL092 60 MG +
NIVOLUMAB 360 MG",,,10,10,,
TRT01P,Planned Treatment for Period 01,,text,"XL092 60 MG +
NIVOLUMAB 480 MG",,,11,11,,
,,,,,,,,,,
PARTR,ADTR Parameters,,text,TUMSTIV,,Tumor State per Investigator,1,1,,
PARTR,ADTR Parameters,,text,LDIAMIV,,Longest Diameter per Investigator (mm),2,2,,
PARTR,ADTR Parameters,,text,SUMDIV,,Sum of Diameters per Investigator (mm),3,3,,
PARTR,ADTR Parameters,,text,TUMSTIR,,Tumor State per Independent Assessor,4,4,,
PARTR,ADTR Parameters,,text,LDIAMIR,,Longest Diameter per Independent Assessor (mm),5,5,,
PARTR,ADTR Parameters,,text,SUMDIR,,Sum of Diameters per Independent Assessor (mm),6,6,,
PARRS,ADRS Parameters,,text,NTRGIVR,,Non-target Response Per Investigator,1,1,,
PARRS,ADRS Parameters,,text,NEWLIVR,,New Lesion Per Investigator,2,2,,
PARRS,ADRS Parameters,,text,OVRLRIVR,,Overall Response Per Investigator,3,3,,
TEVAL,Tumor Evaluator,,text,INVESTIGATOR,,Investigator,,1,,
TUP1CAT,Parameter Category for Tumor Datasets,,text,RECIST 1.1,,,,1,,
PARINT,ADEFFINT Parameters,,text,NBLIVR,,"No Baseline ATA , per Inv using RECIST 1.1 ",1,1,,
PARINT,ADEFFINT Parameters,,text,NPBIVR,,"No Post-Baseline ATA , per Inv using RECIST 1.1 ",2,2,,
PARINT,ADEFFINT Parameters,,text,NBLPBIVR,,"No Baseline and No Post-Baseline ATA , per Inv using RECIST 1.1 ",3,3,,
PARINT,ADEFFINT Parameters,,text,CRESPIVR,,"Date of Confirmed Objective Response, per Inv using RECIST 1.1 ",4,4,,
PARINT,ADEFFINT Parameters,,text,DTHDT,,Date of Death,5,5,,
PARINT,ADEFFINT Parameters,,text,INVPDDT,,"Date of Radiographic PD, per Inv using RECIST 1.1 ",6,6,,
PARINT,ADEFFINT Parameters,,text,LSTFUP,,Lost to Follow-up,7,7,,
PARINT,ADEFFINT Parameters,,text,WDCFDT,,Date of Withdrawal of Full Consent,8,8,,
PARINT,ADEFFINT Parameters,,text,SPNSRDEC,,Date of Withdrawal Per Sponsor Decision,9,9,,
PARINT,ADEFFINT Parameters,,text,LSTALVDT,,Date Last Known Alive,10,10,,
PARINT,ADEFFINT Parameters,,text,SYSACTDT,,Date of First Systemic Non-Radiation Therapy,11,11,,
PARINT,ADEFFINT Parameters,,text,SURGTLDT,,Date of Surgical Resection of Target Lesion(s),12,12,,
PARINT,ADEFFINT Parameters,,text,RADDZDT,,Date of Local Radiation to Soft Tissue for Disease Under Study,13,13,,
PARINT,ADEFFINT Parameters,,text,CUTDT,,Date of Data Cut-Off,14,14,,
SRCDEFF,Source Data for ADEFFINT,,text,ADSL,,,,1,,
SRCDEFF,Source Data for ADEFFINT,,text,ADEFFSUM,,,,2,,
SRCDEFF,Source Data for ADEFFINT,,text,ADRS,,,,3,,
SRCDEFF,Source Data for ADEFFINT,,text,ADPR,,,,4,,
SRCVEFF,Source Variables for ADEFFINT,,text,DTHDT,,,,1,,
SRCVEFF,Source Variables for ADEFFINT,,text,SYSACTDT,,,,2,,
SRCVEFF,Source Variables for ADEFFINT,,text,WDCFDT,,,,3,,
SRCVEFF,Source Variables for ADEFFINT,,text,SYSACTDT,,,,4,,
SRCVEFF,Source Variables for ADEFFINT,,text,LSTALVDT,,,,5,,
SRCVEFF,Source Variables for ADEFFINT,,text,CUTDT,,,,6,,
SRCVEFF,Source Variables for ADEFFINT,,text,RANDDT,,,,7,,
SRCVEFF,Source Variables for ADEFFINT,,text,ADT,,,,8,,
SRCVEFF,Source Variables for ADEFFINT,,text,ASTDT,,,,9,,
PAREFS,ADEFFSUM Parameters,,text,BPBSDIVR,,"At Least 1 BL and Post-BL SoD, per Inv using RECIST 1.1",1,1,,
PAREFS,ADEFFSUM Parameters,,text,MXPSDIVR,,"Maximum Percent Reduction from BL SoD, per Inv using RECIST 1.1",2,2,,
PAREFS,ADEFFSUM Parameters,,text,REDSDIVR,,"Any Reduction in SoD Before 1st PD, per Inv using RECIST 1.1 ",3,3,,
PAREFS,ADEFFSUM Parameters,,text,BNEIVR1,,"Reason 1 For BOR of NE, per Inv using RECIST 1.1 ",5,5,,
PAREFS,ADEFFSUM Parameters,,text,BNEIVR2,,"Reason 2 For BOR of NE, per Inv using RECIST 1.1 ",6,6,,
PAREFS,ADEFFSUM Parameters,,text,BNEIVR3,,"Reason 3 For BOR of NE, per Inv using RECIST 1.1 ",7,7,,
PAREFS,ADEFFSUM Parameters,,text,BNEIVR4,,"Reason 4 For BOR of NE, per Inv using RECIST 1.1 ",8,8,,
PAREFS,ADEFFSUM Parameters,,text,BNEIVR5,,"Reason 5 For BOR of NE, per Inv using RECIST 1.1 ",9,9,,
PAREFS,ADEFFSUM Parameters,,text,CBORIVR,,"Confirmed Best Overall Response, per Inv using RECIST 1.1 ",11,11,,
PAREFS,ADEFFSUM Parameters,,text,TTRIVR,,"Time to Response (months), per Inv using RECIST 1.1  ",12,12,,
SRCDEFFS,Source Data for ADEFFSUM,,text,ADTR,,,,1,,
SRCDEFFS,Source Data for ADEFFSUM,,text,ADRS,,,,2,,
SRCVEFFS,Source Variables for ADEFFSUM,,text,PCHG,,,,1,,
SRCVEFFS,Source Variables for ADEFFSUM,,text,CRIT1FL,,,,2,,
SRCVEFFS,Source Variables for ADEFFSUM,,text,AVALC,,,,3,,
CRIT1ES,Analysis Criterion 1 for ADEFFSUM,,,Objective Response,,,,1,,
CRIT2ES,Analysis Criterion 2 for ADEFFSUM,,,Disease Control,,,,1,,
SRCDTTE,Source Data for ADTTE,,text,ADTTEINT,,,,,,
SRCVTTE,Source Variable for ADTTE,,text,ADT,,,,,,
PARTTE,ADTTE Parameters,,text,OS,,Overall Survival (months),1,1,,
PARTTE,ADTTE Parameters,,text,OSLSFU,,Overall Survival (months) with Lost to Follow-up as Event,2,2,,
PARTTE,ADTTE Parameters,,text,OSSACT,,Overall Survival (months) with Censoring at Systemic Anti-Cancer Therapy,3,3,,
PARTTE,ADTTE Parameters,,text,PFSIVR,,"Progression Free Survival (months), per Inv using RECIST 1.1  ",4,4,,
PARTTE,ADTTE Parameters,,text,DORIVR,,"Duration of Response (months), per Inv using RECIST 1.1  ",5,5,,
PARVS,ADVS Parameters,C66741,text,HEIGHT,C25347,Height (cm),1,4,,
PARVS,ADVS Parameters,C66741,text,WEIGHT,C181552,Weight (kg),2,5,,
PARVS,ADVS Parameters,C66741,text,TEMP,C174446,Temperature (C),3,6,,
PARVS,ADVS Parameters,C66741,text,RESP,C49678,Respiratory Rate (breaths/min),4,7,,
PARVS,ADVS Parameters,C66741,text,PULSE,C49676,Pulse Rate (beats/min),5,5,,
PARVS,ADVS Parameters,C66741,text,SYSBP,C25298,Systolic Blood Pressure (mmHg),6,6,,
PARVS,ADVS Parameters,C66741,text,DIABP,C25299,Diastolic Blood Pressure (mmHg),7,7,,
EGCCAT1,ADEG CHG Categories 1,,text,<= 30 msec,,,,1,,
EGCCAT1,ADEG CHG Categories 1,,text,> 30 msec,,,,2,,
EGCCAT2,ADEG CHG Categories 2,,text,<= 60 msec,,,,1,,
EGCCAT2,ADEG CHG Categories 2,,text,> 60 msec,,,,2,,
EGVCAT1,ADEG AVAL Categories 1,,text,<= 450 msec,,,,1,,
EGVCAT1,ADEG AVAL Categories 1,,text,> 450 msec,,,,2,,
EGVCAT2,ADEG AVAL Categories 2,,text,<= 480 msec,,,,1,,
EGVCAT2,ADEG AVAL Categories 2,,text,> 480 msec,,,,2,,
EGVCAT3,ADEG AVAL Categories 3,,text,<= 500 msec,,,,1,,
EGVCAT3,ADEG AVAL Categories 3,,text,> 500 msec,,,,2,,
PAREG,ADEG Parameters,,text,QTCFSB,,"QTcF Interval, Single Beat (msec)",,1,,
PAREG,ADEG Parameters,,text,INTP,,Interpretation,,2,,
PARRS,ADRS Parameters,,text,OVRLRBI,,Overall Response by CT/MRI Scan per BICR,4,4,,
PARRS,ADRS Parameters,,text,OVRLRPC,,Overall Response by Bone Scan per BICR,5,5,,
PARRS,ADRS Parameters,,text,OVRLRPV,,Overall Response by Bone Scan per Investigator,6,6,,
PARINT,ADEFFINT Parameters,,text,PSAR,,PSA Response,15,15,,
PARINT,ADEFFINT Parameters,,text,PSAP,,PSA Progression,16,16,,
PARINT,ADEFFINT Parameters,,text,NBLPBPSA ,,No Baseline and No Post-Baseline PSA,17,17,,
PARINT,ADEFFINT Parameters,,text,NBLPSA ,,No Baseline PSA,18,18,,
PARINT,ADEFFINT Parameters,,text,NPBLPSA,,No Post-Baseline PSA,19,19,,
PARINT,ADEFFINT Parameters,,text,TCONPSA,,Two Consecutive Missing PSA,20,20,,
PARINT,ADEFFINT Parameters,,text,NBLBI,,No Baseline ATA BIRC ,21,21,,
PARINT,ADEFFINT Parameters,,text,NPBBI,,No Post-Baseline ATA BIRC,22,22,,
PARINT,ADEFFINT Parameters,,text,NBLPBBI,,No Baseline and No Post-Baseline ATA BIRC,23,23,,
PARINT,ADEFFINT Parameters,,text,NBLPC,,No Baseline ATA PCWG3,24,24,,
PARINT,ADEFFINT Parameters,,text,NPBPC,,No Post-Baseline ATA PCWG3,25,25,,
PARINT,ADEFFINT Parameters,,text,NBLPBPC,,No Baseline and No Post-Baseline ATA PCWG3,26,26,,
PARINT,ADEFFINT Parameters,,text,RADDBDT,,Date of Local Radiation to Bone for Disease Under Study,27,27,,
PARINT,ADEFFINT Parameters,,text,IRCPDDT,,"Date of Radiographic PD, per BIRC using RECIST 1.1 ",28,28,,
PARINT,ADEFFINT Parameters,,text,PCWPDDT,,"Date of Radiographic PD, per PCWG3",29,29,,
PARINT,ADEFFINT Parameters,,text,NBLPV,,No Baseline ATA PCWG3 per INV,30,30,,
PARINT,ADEFFINT Parameters,,text,NPBPV,,No Post-Baseline ATA PCWG3 per INV,31,31,,
PARINT,ADEFFINT Parameters,,text,NBLPBPV,,No Baseline and No Post-Baseline ATA PCWG3 per INV,32,32,,
PARINT,ADEFFINT Parameters,,text,PCVPDDT,,"Date of Radiographic PD, per PCWG3 per INV",33,33,,
PAREFS,ADEFFSUM Parameters,,text,CBORPC,,Confirmed Best Overall Response PCWG3,13,13,,
PAREFS,ADEFFSUM Parameters,,text,CBORBI,,Confirmed Best Overall Response BICR,14,14,,
PAREFS,ADEFFSUM Parameters,,text,BNEPC1,,Reason 1 For BOR of NE PCWG3,15,15,,
PAREFS,ADEFFSUM Parameters,,text,BNEPC2,,Reason 2 For BOR of NE PCWG3,16,16,,
PAREFS,ADEFFSUM Parameters,,text,BNEPC3,,Reason 3 For BOR of NE PCWG3,17,17,,
PAREFS,ADEFFSUM Parameters,,text,BNEPC4,,Reason 4 For BOR of NE PCWG3,18,18,,
PAREFS,ADEFFSUM Parameters,,text,BNEPC5,,Reason 5 For BOR of NE PCWG3,19,19,,
PAREFS,ADEFFSUM Parameters,,text,BNEBI1,,Reason 1 For BOR of NE BICR,20,20,,
PAREFS,ADEFFSUM Parameters,,text,BNEBI2,,Reason 2 For BOR of NE BICR,21,21,,
PAREFS,ADEFFSUM Parameters,,text,BNEBI3,,Reason 3 For BOR of NE BICR,22,22,,
PAREFS,ADEFFSUM Parameters,,text,BNEBI4,,Reason 4 For BOR of NE BICR,23,23,,
PAREFS,ADEFFSUM Parameters,,text,BNEBI5,,Reason 5 For BOR of NE BICR,24,24,,
PARTTE,ADTTE Parameters,,text,PFSPC,,Progression Free Survival (months) PCWG3 per BICR,6,6,,
PARTTE,ADTTE Parameters,,text,PFSBI,,Progression Free Survival (months) BICR,7,7,,
PARTTE,ADTTE Parameters,,text,PSARTTE,,Time to PSA Response (weeks),8,8,,
PARTTE,ADTTE Parameters,,text,PSAPTTE,,Time to PSA Progression (months),9,9,,
PARTTE,ADTTE Parameters,,text,PFSPV,,Progression Free Survival (months) PCWG3 per INV,10,10,,
PARAETT,ADAETTE Parameters,,text,TTONADI,,Time to Onset of ADRENAL INSUFFICIENCY (weeks),1,1,,
PARAETT,ADAETTE Parameters,,text,TTONDIC,,Time to Onset of DIARRHEA/COLITIS (weeks),2,2,,
PARAETT,ADAETTE Parameters,,text,TTONDMY,,Time to Onset of Demyelination (weeks),3,3,,
PARAETT,ADAETTE Parameters,,text,TTONDBM,,Time to Onset of Diabetes mellitus (weeks),4,4,,
PARAETT,ADAETTE Parameters,,text,TTONENC,,Time to Onset of Encephalitis (weeks),5,5,,
PARAETT,ADAETTE Parameters,,text,TTONGVH,,Time to Onset of Graft versus host disease (weeks),6,6,,
PARAETT,ADAETTE Parameters,,text,TTONGBS,,Time to Onset of Guillain-Barre syndrome (weeks),7,7,,
PARAETT,ADAETTE Parameters,,text,TTONHTY,,Time to Onset of HYPERTHYROIDISM (weeks),8,8,,
PARAETT,ADAETTE Parameters,,text,TTONHPH,,Time to Onset of HYPOPHYSITIS (weeks),9,9,,
PARAETT,ADAETTE Parameters,,text,TTONHEP,,Time to Onset of Hepatitis (weeks),10,10,,
PARAETT,ADAETTE Parameters,,text,TTONHSY,,Time to Onset of Hypersensitivity (weeks),11,11,,
PARAETT,ADAETTE Parameters,,text,TTONHOT,,Time to Onset of Hypothyroidism (weeks),12,12,,
PARAETT,ADAETTE Parameters,,text,TTONMYS,,Time to Onset of Myasthenic syndrome (weeks),13,13,,
PARAETT,ADAETTE Parameters,,text,TTONMYC,,Time to Onset of Myocarditis (weeks),14,14,,
PARAETT,ADAETTE Parameters,,text,TTONMRH,,Time to Onset of Myositis and Rhabdomyolysis (weeks),15,15,,
PARAETT,ADAETTE Parameters,,text,TTONNRD,,Time to Onset of Nephritis and Renal Dysfunction (weeks),16,16,,
PARAETT,ADAETTE Parameters,,text,TTONPNE,,Time to Onset of PNEUMONITIS (weeks),17,17,,
PARAETT,ADAETTE Parameters,,text,TTONPAN,,Time to Onset of Pancreatitis (weeks),18,18,,
PARAETT,ADAETTE Parameters,,text,TTONRSH,,Time to Onset of Rash (weeks),19,19,,
PARAETT,ADAETTE Parameters,,text,TTONTHY,,Time to Onset of Thyroiditis (weeks),20,20,,
PARAETT,ADAETTE Parameters,,text,TTONUVE,,Time to Onset of Uveitis (weeks),21,21,,
PARAETT,ADAETTE Parameters,,text,TTORRMG,,Time to Onset of Rela Meningitis (weeks),22,22,,
PARAETT,ADAETTE Parameters,,text,TTORRTP,,Time to Onset of Rela Troponin (weeks),23,23,,
PARAETT,ADAETTE Parameters,,text,TTOXATE,,Time to Onset of Arterial thromboembolic events (weeks),24,24,,
PARAETT,ADAETTE Parameters,,text,TTOXGPF,,Time to Onset of GI perforation and fistula (weeks),25,25,,
PARAETT,ADAETTE Parameters,,text,TTOXHMD,,Time to Onset of Haemorrhage (weeks),26,26,,
PARAETT,ADAETTE Parameters,,text,TTOXHTX,,Time to Onset of Hepatotoxicity (weeks),27,27,,
PARAETT,ADAETTE Parameters,,text,TTOXHPT,,Time to Onset of Hypertension (weeks),28,28,,
PARAETT,ADAETTE Parameters,,text,TTOXPRT,,Time to Onset of Proteinuria (weeks),29,29,,
PARAETT,ADAETTE Parameters,,text,TTOXVMT,,Time to Onset of Venous/Mixed thromboembolic events (weeks),30,30,,
PARAETT,ADAETTE Parameters,,text,TTOXWDC,,Time to Onset of Wound complication (weeks),31,31,,
PARAETT,ADAETTE Parameters,,text,TTRNADI,,Time to Resolution of ADRENAL INSUFFICIENCY (weeks),32,32,,
PARAETT,ADAETTE Parameters,,text,TTRNDIC,,Time to Resolution of DIARRHEA/COLITIS (weeks),33,33,,
PARAETT,ADAETTE Parameters,,text,TTRNDMY,,Time to Resolution of Demyelination (weeks),34,34,,
PARAETT,ADAETTE Parameters,,text,TTRNDBM,,Time to Resolution of Diabetes mellitus (weeks),35,35,,
PARAETT,ADAETTE Parameters,,text,TTRNENC,,Time to Resolution of Encephalitis (weeks),36,36,,
PARAETT,ADAETTE Parameters,,text,TTRNGVH,,Time to Resolution of Graft versus host disease (weeks),37,37,,
PARAETT,ADAETTE Parameters,,text,TTRNGBS,,Time to Resolution of Guillain-Barre syndrome (weeks),38,38,,
PARAETT,ADAETTE Parameters,,text,TTRNHTY,,Time to Resolution of HYPERTHYROIDISM (weeks),39,39,,
PARAETT,ADAETTE Parameters,,text,TTRNHPH,,Time to Resolution of HYPOPHYSITIS (weeks),40,40,,
PARAETT,ADAETTE Parameters,,text,TTRNHEP,,Time to Resolution of Hepatitis (weeks),41,41,,
PARAETT,ADAETTE Parameters,,text,TTRNHSY,,Time to Resolution of Hypersensitivity (weeks),42,42,,
PARAETT,ADAETTE Parameters,,text,TTRNHOT,,Time to Resolution of Hypothyroidism (weeks),43,43,,
PARAETT,ADAETTE Parameters,,text,TTRNMYS,,Time to Resolution of Myasthenic syndrome (weeks),44,44,,
PARAETT,ADAETTE Parameters,,text,TTRNMYC,,Time to Resolution of Myocarditis (weeks),45,45,,
PARAETT,ADAETTE Parameters,,text,TTRNMRH,,Time to Resolution of Myositis and Rhabdomyolysis (weeks),46,46,,
PARAETT,ADAETTE Parameters,,text,TTRNNRD,,Time to Resolution of Nephritis and Renal Dysfunction (weeks),47,47,,
PARAETT,ADAETTE Parameters,,text,TTRNPNE,,Time to Resolution of PNEUMONITIS (weeks),48,48,,
PARAETT,ADAETTE Parameters,,text,TTRNPAN,,Time to Resolution of Pancreatitis (weeks),49,49,,
PARAETT,ADAETTE Parameters,,text,TTRNRSH,,Time to Resolution of Rash (weeks),50,50,,
PARAETT,ADAETTE Parameters,,text,TTRNTHY,,Time to Resolution of Thyroiditis (weeks),51,51,,
PARAETT,ADAETTE Parameters,,text,TTRNUVE,,Time to Resolution of Uveitis (weeks),52,52,,
PARAETT,ADAETTE Parameters,,text,TTRRRMG,,Time to Resolution of Rela Meningitis (weeks),53,53,,
PARAETT,ADAETTE Parameters,,text,TTRRRTP,,Time to Resolution of Rela Troponin (weeks),54,54,,
PARAETT,ADAETTE Parameters,,text,TTRXATE,,Time to Resolution of Arterial thromboembolic events (weeks),55,55,,
PARAETT,ADAETTE Parameters,,text,TTRXGPF,,Time to Resolution of GI perforation and fistula (weeks),56,56,,
PARAETT,ADAETTE Parameters,,text,TTRXHMD,,Time to Resolution of Haemorrhage (weeks),57,57,,
PARAETT,ADAETTE Parameters,,text,TTRXHTX,,Time to Resolution of Hepatotoxicity (weeks),58,58,,
PARAETT,ADAETTE Parameters,,text,TTRXHPT,,Time to Resolution of Hypertension (weeks),59,59,,
PARAETT,ADAETTE Parameters,,text,TTRXPRT,,Time to Resolution of Proteinuria (weeks),60,60,,
PARAETT,ADAETTE Parameters,,text,TTRXVMT,,Time to Resolution of Venous/Mixed thromboembolic events (weeks),61,61,,
PARAETT,ADAETTE Parameters,,text,TTRXWDC,,Time to Resolution of Wound complication (weeks),62,62,,
LBP2CAT,ADLB Parameter Category 2,,text,BI-DIRECTIONAL GRADING,,,,1,,
LBP2CAT,ADLB Parameter Category 2,,text,UNI-DIRECTIONAL GRADING,,,,2,,
